Paulson & Co’s Editas Medicine EDIT Stock Holding History

Paulson & Co’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-50,000	Closed	-$839K	–	64
2017 Q2	$839K	Hold	50,000	–	–	0.01%	102
2017 Q1	$1.12M	Buy	+50,000	New	+$1.04M	0.01%	90

Other funds holding EDIT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PVMCV

Polaris Venture Management Co VI Boston, Massachusetts $43.1M AUM 78.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Paulson & Co's EDIT Position: Q3 2017 in Review

Paulson & Co sold out of Editas Medicine (EDIT) in Q3 2017, closing a stake of 50,000 shares — an estimated $839K sold.

Paulson & Co first reported a position in EDIT in Q1 2017 and held it in 2 quarters. The position peaked at $1.12M in Q1 2017. 116 funds tracked by Wall St. Rank hold EDIT as of Q3 2017.

Paulson & Co reported no remaining Editas Medicine position as of Q3 2017 after selling out during the quarter.
Paulson & Co sold 50,000 Editas Medicine shares in Q3 2017, an estimated $839K.
Paulson & Co first reported a position in Editas Medicine in Q1 2017 and held it in 2 quarters.
Paulson & Co's Editas Medicine position peaked at $1.12M in Q1 2017.
116 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.